However, the mechanism of thrombosis associated with weakly activating JAK2 germline mutations has not been described, nor it is known whether these variants modulate hematopoietic stem cell (HSC)/progenitor function as proposed for other contributors to germline MPN risk [3]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.